Blood laboratory testing for early prediction of preeclampsia: chasing the finish line or at the starting blocks?

References

• American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol, 2013;122:1122–31.
   PubMed Web of Science ®Google Scholar
• Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–7.
   PubMed Web of Science ®Google Scholar
• Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170:1–7.
   PubMed Web of Science ®Google Scholar
• The National Institute for Health and Care Excellence, 2010; [cited 2016 May 11]. Available from: www.nice.org.uk/guidance/CG107/Guidance.
   Google Scholar
• Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631–44.
   PubMed Web of Science ®Google Scholar
• Cnossen JS, ter Riet G, Mol BW, van der Post JA, Leeflang MM, Meads CA, et al. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand. 2009;88:758–65.
   PubMed Web of Science ®Google Scholar
• Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, et al. Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol. 2015;46:419–23.
   PubMed Web of Science ®Google Scholar
• Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791–8.
   PubMed Web of Science ®Google Scholar
• Roberge S, Giguère Y, Villa P, Nicolaides K, Vainio M, Forest JC, et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol. 2012;29:551–6.
   PubMed Web of Science ®Google Scholar
• Giguère Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem. 2010;56:361–75.
   PubMed Web of Science ®Google Scholar
• Forest JC, Charland M, Massé J, Bujold E, Rousseau F, Lafond J, et al. Candidate biochemical markers for screening of pre-eclampsia in early pregnancy. Clin Chem Lab Med. 2012;50:973–84.
   PubMed Web of Science ®Google Scholar
• Jadli A, Sharma N, Damania K, Satoskar P, Bansal V, Ghosh K, et al. Promising prognostic markers of preeclampsia: new avenues in waiting. Thromb Res. 2015;136:189–95.
   PubMed Web of Science ®Google Scholar
• Wu P, van den Berg C, Alfirevic Z, O'Brien S, Röthlisberger M, Baker PN, et al. Early pregnancy biomarkers in pre-eclampsia: a systematic review and meta-analysis. Int J Mol Sci. 2015;16:23035–56.
   PubMed Web of Science ®Google Scholar
• Fisher SJ. Why is placentation abnormal in preeclampsia?. Am J Obstet Gynecol. 2015;213:S115–22.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10:466–80.
   PubMed Web of Science ®Google Scholar
• Januar V, Desoye G, Novakovic B, Cvitic S, Saffery R. Epigenetic regulation of human placental function and pregnancy outcome: considerations for causal inference. Am J Obstet Gynecol. 2015;213:S182–96.
   PubMed Web of Science ®Google Scholar
• Griner PF, Mayewski RJ, Mushlin AI, Greenland P. Selection and interpretation of diagnostic tests and procedures. Principles and applications. Ann Intern Med. 1981;94:557–92.
   PubMed Web of Science ®Google Scholar
• Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol. 2012;119:1234–42.
   PubMed Web of Science ®Google Scholar
• Youssef A, Righetti F, Morano D, Rizzo N, Farina A. Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (> 34 weeks) pre-eclampsia. Prenat Diagn. 2011;31:1141–6.
   PubMed Web of Science ®Google Scholar
• Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn. 2005;25:949–53.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;29:128–34.
   PubMed Web of Science ®Google Scholar
• Goetzinger KR, Zhong Y, Cahill AG, Odibo L, Macones GA, Odibo AO. Efficiency of first-trimester uterine artery Doppler, a-disintegrin and metalloprotease 12, pregnancy-associated plasma protein a, and maternal characteristics in the prediction of preeclampsia. J Ultrasound Med. 2013;32:1593–600.
   PubMed Web of Science ®Google Scholar
• Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol. 2010;35:662–70.
   PubMed Web of Science ®Google Scholar
• Yu J, Shixia CZ, Wu Y, Duan T. Inhibin A, activin A, placental growth factor and uterine artery Doppler pulsatility index in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2011;37:528–33.
   PubMed Web of Science ®Google Scholar
• Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011;31:66–74.
   PubMed Web of Science ®Google Scholar
• Odibo AO, Zhong Y, Goetzinger KR, Odibo L, Bick JL, Bower CR, et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta. 2011;32:598–602.
   PubMed Web of Science ®Google Scholar
• Acestor N, Goett J, Lee A, Herrick TM, Engelbrecht SM, Harner-Jay CM, et al. Towards biomarker-based tests that can facilitate decisions about prevention and management of preeclampsia in low-resource settings. Clin Chem Lab Med. 2016;54:17–27.
   PubMed Web of Science ®Google Scholar
• Llurba E, Crispi F, Verlohren S. Update on the pathophysiological implications and clinical role of angiogenic factors in pregnancy. Fetal Diagn Ther. 2015;37:81–92.
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–9.
   PubMed Web of Science ®Google Scholar
• Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am. 2010;37:239–53.
   PubMed Web of Science ®Google Scholar
• Lee ES, Oh MJ, Jung JW, Lim JE, Seol HJ, Lee KJ, et al. The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia. J Korean Med Sci. 2007;22:94–8.
   PubMed Web of Science ®Google Scholar
• Odibo AO, Rada CC, Cahill AG, Goetzinger KR, Tuuli MG, Odibo L, et al. First trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia. J Perinatol. 2013;33:670–4.
   PubMed Web of Science ®Google Scholar
• Kurtoglu E, Avci B, Kokcu A, Celik H, Cengiz Dura M, Malatyalioglu E, et al. Serum VEGF and PGF may be significant markers in prediction of severity of preeclampsia. J Matern Fetal Neonatal Med. 2016;29:1987–92.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.
   PubMed Web of Science ®Google Scholar
• Salahuddin S, Wenger JB, Zhang D, Thadhani R, Karumanchi SA, Rana S. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. Hypertens Pregnancy. 2016;35:330–45.
   PubMed Web of Science ®Google Scholar
• Engels T, Pape J, Schoofs K, Henrich W, Verlohren S. Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders. Hypertens Pregnancy. 2013;32:459–73.
   PubMed Web of Science ®Google Scholar
• Jardim LL, Rios DR, Perucci LO, de Sousa LP, Gomes KB, Dusse LM. Is the imbalance between pro-angiogenic and anti-angiogenic factors associated with preeclampsia?. Clin Chim Acta. 2015;447:34–8.
   PubMed Web of Science ®Google Scholar
• Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13–22.
   PubMed Web of Science ®Google Scholar
• Baltajian K, Bajracharya S, Salahuddin S, Berg AH, Geahchan C, Wenger JB, et al. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Am J Obstet Gynecol. 2016;215:89.e1–.e10.
   Web of Science ®Google Scholar
• Kim MY, Buyon JP, Guerra MM, Rana S, Zhang D, Laskin CA, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016;214:108.e1–14.
   Web of Science ®Google Scholar
• Maynard SE, Crawford SL, Bathgate S, Yan J, Robidoux L, Moore M, et al. Gestational angiogenic biomarker patterns in high risk preeclampsia groups. Am J Obstet Gynecol. 2013;209:53.e1–9.
   PubMed Web of Science ®Google Scholar
• Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One. 2010;5:e13263.
   PubMed Web of Science ®Google Scholar
• McElrath TF, Lim KH, Pare E, Rich-Edwards J, Pucci D, Troisi R, et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol. 2012;207:407.e1–7.
   Google Scholar
• Widmer M, Cuesta C, Khan KS, Conde-Agudelo A, Carroli G, Fusey S, et al. Accuracy of angiogenic biomarkers at ≤20 weeks’ gestation in predicting the risk of pre-eclampsia: a WHO multicentre study. Pregnancy Hypertens. 2015;5:330–8.
   PubMed Web of Science ®Google Scholar
• Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenat Diagn. 2015;35:183–91.
   PubMed Web of Science ®Google Scholar
• Andersen LB, Dechend R, Jørgensen JS, Luef BM, Nielsen J, Barington T, et al. Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort. Hypertens Pregnancy. 2016;35:405–19.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans N, Nicolaides K. Low levels of maternal serum PAPP-A in the first trimester and the risk of preeclampsia. Prenat Diagn. 2008;28:7–10.
   PubMed Web of Science ®Google Scholar
• Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CD, et al. First trimester maternal PAPP-A and free beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population based screening study (The FaSTER trial). Am J Obstet Gynecol. 2004;191:1446–51.
   PubMed Web of Science ®Google Scholar
• Bersinger NA, Smarason AK, Muttukrishna S, Groome NP, Redman CW. Women with pre-eclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin-A, activin-A and soluble E-selectin. Hypertens Pregnancy. 2003;22:45–55.
   PubMed Web of Science ®Google Scholar
• Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J. Clin. Endocrinol. Metab. 2002;87:1762–7.
   PubMed Web of Science ®Google Scholar
• Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J, et al. Serum inhibin-A and activin-A are elevated prior to the onset of pre-eclampsia. Hum Reprod. 2000;15:1640–5.
   PubMed Web of Science ®Google Scholar
• Ree PH, Hahn WB, Chang SW, Jung SH, Kang JH, Cha DH, et al. Early detection of pre-eclampsia using inhibin-A and other second-trimester serum markers. Fetal Diagn Ther. 2011;29:280–6.
   PubMed Web of Science ®Google Scholar
• Hui D, Okun N, Murphy K, Kingdom J, Uleryk E, Shah PS. Combinations of maternal serum markers to predict preeclampsia, small for gestational age, and stillbirth: a systematic review. J Obstet Gynaecol Can. 2012;34:142–53.
   PubMedGoogle Scholar
• Zhong Y, Zhu F, Ding Y. Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis. BMC Pregnancy. Childbirth 2015;15:191.
   PubMed Web of Science ®Google Scholar
• Allen RE, Rogozinska E, Cleverly K, Aquilina J, Thangaratinam S. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;182:194–201.
   PubMed Web of Science ®Google Scholar
• Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H. Longitudinal determination of serum placental protein 13 during development of pre-eclampsia. Fetal Diagn Ther. 2008;24:230–6.
   PubMed Web of Science ®Google Scholar
• Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H, et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG. 2008;115:1465–72.
   PubMed Web of Science ®Google Scholar
• Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, et al. First-trimester placental protein 13 screening for pre-eclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007;197:35.e1–7.
   PubMed Web of Science ®Google Scholar
• Schneuer FJ, Nassar N, Khambalia AZ, Tasevski V, Guilbert C, Ashton AW, et al. First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: in-house study and systematic review. Placenta. 2012;33:735–40.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Nicolaides KH. Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet Gynecol. 2008;32:622–6.
   PubMed Web of Science ®Google Scholar
• El-Gharib MN, Morad M. Maternal serum inhibin-A for predicting preeclampsia. J Matern Fetal Neonatal Med. 2011;24:595–9.
   PubMed Web of Science ®Google Scholar
• Sebire NJ, Roberts L, Noble P, Wallace E, Nicolaides KH. Raised maternal serum inhibin A concentration at 10 to 14 weeks of gestation is associated with pre-eclampsia. BJOG. 2000;107:795–7.
   PubMed Web of Science ®Google Scholar
• Cui Y, Wang W, Dong N, Lou J, Srinivasan DK, Cheng W, et al. Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy. Nature. 2012;484:246–50.
   PubMed Web of Science ®Google Scholar
• Zaki MA, El-Banawy SE-DS, El-Gammal HH. Plasma soluble corin and N-terminal pro- atrial natriurectic peptide levels in pregnancy induced hypertension. Pregnancy Hypertens. 2012;2:48–52.
   PubMed Web of Science ®Google Scholar
• Khalil A, Maiz N, Garcia-Mandujano R, Elkhouli M, Nicolaides KH. Longitudinal changes in maternal corin and mid-regional proatrial natriuretic peptide in women at risk of pre-eclampsia. Ultrasound Obstet Gynecol. 2015;45:190–8.
   PubMed Web of Science ®Google Scholar
• Holwerda DA. A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. Eur J Biochem. 1972;28:334–9.
   PubMedGoogle Scholar
• Yeung EH, Liu A, Mills JL, Zhang C, Männistö T, Lu Z, et al. Increased levels of copeptin before clinical diagnosis of preelcampsia. Hypertension. 2014;64:1362–7.
   PubMed Web of Science ®Google Scholar
• Birdir C, Janssen K, Stanescu AD, Enekwe A, Kasimir-Bauer S, Gellhaus A, et al. Maternal serum copeptin, MR-proANP and procalcitonin levels at 11-13 weeks gestation in the prediction of preeclampsia. Arch Gynecol Obstet. 2015;292:1033–42.
   PubMed Web of Science ®Google Scholar
• Can M, Sancar E, Harma M, Guven B, Mungan G, Acikgoz S. Inflammatory markers in preeclamptic patients. Clin Chem Lab Med. 2011;49:1469–72.
   PubMed Web of Science ®Google Scholar
• Mihu D, Razvan C, Malutan A, Mihaela C. Evaluation of maternal systemic inflammatory response in preeclampsia. Taiwan J Obstet Gynecol. 2015;54:160–6.
   PubMed Web of Science ®Google Scholar
• Hamai Y, Fujii T, Yamashita T, Nishina H, Kozuma S, Mikami Y, et al. Evidence for an elevation in serum IL-2 and tumour necrosis factor-alpha levels before the clinical manifestations of preeclampsia. Am J Reprod Immunol. 1997;38:89–93.
   PubMed Web of Science ®Google Scholar
• Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension. 2004;44:708–14.
   PubMed Web of Science ®Google Scholar
• Siljee JE, Wortelboer EJ, Koster MP, Imholz S, Rodenburg W, Visser GH, et al. Identification of interleukin-1 beta, but no other inflammatory proteins, as an early onset pre-eclampsia biomarker in first trimester serum by bead-based multiplexed immunoassays. Prenat Diagn. 2013;33:1183–8.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Kwon JY, Kim MA, Park YW, Kim YH. Maternal serum highly sensitive C-reactive protein in normal pregnancy and pre-eclampsia. Int J Gynaecol Obstet. 2007;98:105–9.
   PubMed Web of Science ®Google Scholar
• Montagnana M, Lippi G, Albiero A, Salvagno GL, Franchi M, Guidi GC. Serum pro-inflammatory cytokines in physiological and pre-eclamptic pregnancies. Gynecol Endocrinol. 2008;24:113–16.
   PubMed Web of Science ®Google Scholar
• Liu H, Wu J, Wang H, Sheng L, Tang N, Li Y, Hao T. Association of serum omentin-1 concentrations with the presence and severity of preeclampsia. Ann Clin Biochem. 2015;52:245–50.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang Y, Wang Y, Li J, Liu R, Liu H. Decreased levels of serum nesfatin-1 in patients with preeclampsia. Biomarkers. 2014;19:402–6.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhao F, Lin F, Xiang H, Wang N, Ye D, Huang Y. Preeclampsia is associated with a deficiency of lipoxin A4, an endogenous anti-inflammatory mediator. Fertil Steril. 2014;102:282–290.e4.
   PubMed Web of Science ®Google Scholar
• Cetin I, Cozzi V, Pasqualini F, Nebuloni M, Garlanda C, Vago L, et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in pre-eclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2006;194:1347–53.
   PubMed Web of Science ®Google Scholar
• Tangerås LH, Austdal M, Skråstad RB, Salvesen KÅ, Austgulen R, Bathen TF, et al. Distinct first trimester cytokine profiles for gestational hypertension and preeclampsia. Arterioscler Thromb Vasc Biol. 2015;35:2478–85.
   PubMed Web of Science ®Google Scholar
• Roh S, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M. Chemerin – a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun. 2007;362:1013–18.
   PubMed Web of Science ®Google Scholar
• Xu QL, Zhu M, Jin Y, Wang N, Xu HX, Quan LM, et al. The predictive value of the first-trimester maternal serum chemerin level for pre-eclampsia. Peptides. 2014;62:150–4.
   PubMed Web of Science ®Google Scholar
• Malek A, Bersinger NA, Di Santo S, Mueller MD, Sager R, Schneider H. et al. C-reactive protein production in term human placental tissue. Placenta. 2006;27:619–25.
   PubMed Web of Science ®Google Scholar
• Kashanian M, Aghbali F, Mahali N. Evaluation of the diagnostic value of the first-trimester maternal serum high-sensitivity C-reactive protein level for prediction of pre-eclampsia. J Obstet Gynaecol Res. 2013;39:1549–54.
   PubMed Web of Science ®Google Scholar
• Karinen L, Leinonen M, Bloigu A, Paldanius M, Koskela P, Saikku P. et al. Maternal serum chlamydia pneumoniae antibodies and CRP levels in women with pre-eclampsia and gestational hypertension. Hypertens Pregnancy. 2008;27:143–58.
   PubMed Web of Science ®Google Scholar
• Ismail SK, Higgins JR. Hemostasis in pre-eclampsia. Semin Thromb Hemost. 2011;37:111–17.
   PubMed Web of Science ®Google Scholar
• Moraes D, Munhoz TP, Pinheiro da Costa BE, Hentschke MR, Sontag F, Silveira Lucas L, et al. Immature platelet fraction in hypertensive pregnancy. Platelets. 2016;27:333–7.
   PubMed Web of Science ®Google Scholar
• Kanat-Pektas M, Yesildager U, Tuncer N, Arioz DT, Nadirgil-Koken G, Yilmazer M. Could mean platelet volume in late first trimester of pregnancy predict intrauterine growth restriction and pre-eclampsia?. J Obstet Gynaecol Res. 2014;40:1840–5.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol. 1999;6:342–8.
   PubMedGoogle Scholar
• Holthe MR, Staff AC, Berge LN, Lyberg T. Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women. Am J Obstet Gynecol. 2004;190:1128–34.
   PubMed Web of Science ®Google Scholar
• Konijnenberg A, Stokkers EW, van der Post JA, Schaap MC, Boer K, Bleker OP, et al. Extensive platelet activation in pre-eclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol. 1997;176:461–9.
   PubMed Web of Science ®Google Scholar
• Yoneyama Y, Suzuki S, Sawa R, Kiyokawa Y, Power GG, Araki T. Plasma adenosine levels and P-selectin expression on platelets in pre-eclampsia. Obstet. Gynecol. 2001;97:366–70.
   PubMed Web of Science ®Google Scholar
• Freitas LG, Sathler-Avelar R, Vitelli-Avelar DM, Bela SR, Teixeira-Carvalho A, Carvalho M, et al. Preeclampsia: integrated network model of platelet biomarkers interaction as a tool to evaluate the hemostatic/immunological interface. Clin Chim Acta. 2014;436:193–201.
   PubMed Web of Science ®Google Scholar
• Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost. 2005;3:1590–6.
   PubMed Web of Science ®Google Scholar
• Heyl W, Handt S, Reister F, Gehlen J, Schroder W, Mittermayer C, et al. Elevated soluble adhesion molecules in women with pre-eclampsia. Do cytokines like tumour necrosis factor-alpha and interleukin-1beta cause endothelial activation. Eur. J Obstet Gynecol Reprod Biol. 1999;86:35–41.
   PubMed Web of Science ®Google Scholar
• Bosio PM, Cannon S, McKenna PJ, O'Herlihy C, Conroy R, Brady H. Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia. BJOG. 2001;108:709–15.
   PubMed Web of Science ®Google Scholar
• Banzola I, Farina A, Concu M, Sekizawa A, Purwosunu Y, Strada I, et al. Performance of a panel of maternal serum markers in predicting preeclampsia at 11–15 weeks’ gestation. Prenat Diagn. 2007;27:1005–10.
   PubMed Web of Science ®Google Scholar
• Akolekar R, Veduta A, Minekawa R, Chelemen T, Nicolaides KH. Maternal plasma P-selectin at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Hypertens Pregnancy. 2011;30:311–21.
   PubMed Web of Science ®Google Scholar
• Dundar O, Yoruk P, Tutuncu L, Erikci AA, Muhcu M, Ergur AR, et al. Longitudinal study of platelet size changes in gestation and predictive power of elevated MPV in development of pre-eclampsia. Prenat Diagn. 2008;28:1052–6.
   PubMed Web of Science ®Google Scholar
• Kirbas A, Ersoy AO, Daglar K, Dikici T, Biberoglu EH, Kirbas O, et al. Prediction of preeclampsia by first trimester combined test and simple complete blood count parameters. J Clin Diagn Res. 2015;9:QC20–3.
   PubMed Web of Science ®Google Scholar
• Perry KG, Jr, Martin JN. Jr., Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia. Clin Obstet Gynecol. 1992;35:338–50.
   PubMed Web of Science ®Google Scholar
• Pinheiro MB, Gomes KB, Dusse LM. Fibrinolytic system in preeclampsia. Clin Chim Acta. 2013;416:67–71.
   PubMed Web of Science ®Google Scholar
• Hunt BJ, Missfelder-Lobos H, Parra-Cordero M, Fletcher O, Parmar K, Lefkou E, et al. Pregnancy outcome and fibrinolytic, endothelial and coagulation markers in women undergoing uterine artery Doppler screening at 23 weeks. J Thromb Haemost. 2009;7:955–61.
   PubMed Web of Science ®Google Scholar
• Sartori MT, Serena A, Saggiorato G, Campei S, Faggian D, Pagnan A, et al. Variations in fibrinolytic parameters and inhibin-A in pregnancy: related hypertensive disorders. J Thromb Haemost. 2008;6:352–8.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Inoue T, Hoshimoto K, Negishi H, Ohkura T, Inaba N. Characterization of five marker levels of the hemostatic system and endothelial status in normotensive pregnancy and pre-eclampsia. Eur J Haematol. 2002;69:297–302.
   PubMed Web of Science ®Google Scholar
• Reinthaller A, Mursch-Edlmayr G, Tatra G. Thrombin-antithrombin III complex levels in normal pregnancy with hypertensive disorders and after delivery. Br J Obstet Gynaecol. 1990;97:506–10.
   PubMedGoogle Scholar
• Cadroy Y, Grandjean H, Pichon J, Desprats R, Berrebi A, Fournié A, et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol. 1993;100:416–20.
   PubMedGoogle Scholar
• De Boer K, Ten C, Ate JW, Sturk A, Borm JJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol. 1989;160:95–100.
   PubMed Web of Science ®Google Scholar
• Hale SA, Sobel B, Benvenuto A, Schonberg A, Badger GJ, Bernstein IM. Coagulation and fibrinolytic system protein profiles in women with normal pregnancies and pregnancies complicated by hypertension. Pregnancy Hypertens. 2012;2:152–7.
   PubMed Web of Science ®Google Scholar
• Han L, Liu X, Li H, Zou J, Yang Z, Han J, et al. Blood coagulation parameters and platelet indices: changes in normal and preeclamptic pregnancies and predictive values for preeclampsia. PLoS One. 2014;9:e114488.
   PubMed Web of Science ®Google Scholar
• Martin A, Krishna I, Badell M, Samuel A. Can the quantity of cell-free fetal DNA predict preeclampsia: a systematic review. Prenat Diagn. 2014;34:685–91.
   PubMed Web of Science ®Google Scholar
• Hahn S, Rusterholz C, Hosli I, Lapaire O. Cell-free nucleic acids as potential markers for preeclampsia. Placenta. 2011;32:S17–20.
   PubMedGoogle Scholar
• Zhao Z, Moley KH, Gronowski AM. Diagnostic potential for miRNAs as biomarkers for pregnancy-specific diseases. Clin Biochem. 2013;46:953–60.
   PubMed Web of Science ®Google Scholar
• Ura B, Feriotto G, Monasta L, Bilel S, Zweyer M, Celeghini C. Potential role of circulating microRNAs as early markers of preeclampsia. Taiwan J Obstet Gynecol. 2014;53:232–4.
   PubMed Web of Science ®Google Scholar
• Gunel T, Zeybek YG, Akçakaya P, Kalelioğlu I, Benian A, Ermis H, et al. Serum microRNA expression in pregnancies with preeclampsia. Genet Mol Res. 2012;10:4034.
   Web of Science ®Google Scholar
• Lo ES, Lo YM, Hjelm NM, Thilaganathan B. Transfer of nucleated maternal cells into fetal circulation during the second trimester of pregnancy. Br J Haematol. 1998;100:605–6.
   PubMed Web of Science ®Google Scholar
• Lau TW, Leung TN, Chan LY, Lau TK, Chan KC, Tam WH, et al. Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin Chem. 2002;48:2141–6.
   PubMed Web of Science ®Google Scholar
• Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485–7.
   PubMed Web of Science ®Google Scholar
• Lo YM, Leung TN, Tein MSC, Sargent IL, Zhang J, Lau TK, et al. Quantitative abnormalities of fetal DNA in maternal serum in pre-eclampsia. Clin Chem. 1999;45:184–8.
   PubMed Web of Science ®Google Scholar
• Leung TN, Zhang J, Lau TK, Chan LY, Lo YM. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem. 2001;47:137–9.
   PubMed Web of Science ®Google Scholar
• Zhong XY, Holzgreve W, Hahn S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy. 2002;21:77–83.
   PubMed Web of Science ®Google Scholar
• Vlková B, Turňa J, Celec P. Fetal DNA in maternal plasma in preeclamptic pregnancies. Hypertens Pregnancy. 2015;34:36–49.
   PubMed Web of Science ®Google Scholar
• Zimmermann B, El-Sheikhah A, Nicolaides K, Holzgreve W, Hahn S. Optimized real-time quantitative PCR measurement of male fetal DNA in maternal plasma. Clin Chem. 2005;51:1598–604.
   PubMed Web of Science ®Google Scholar
• Chim SS, Tong YK, Chiu RW, Lau TK, Leung TN, Chan LY, et al. Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proc Natl Acad Sci USA. 2005;102:14753–8.
   PubMed Web of Science ®Google Scholar
• Rolnik DL, O'Gorman N, Fiolna M, van den Boom D, Nicolaides KH, Poon LC. Maternal plasma cell-free DNA in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2015;45:106–11.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim HJ, Park SY, Han YJ, Choi JS, Ryu HM. Early prediction of hypertensive disorders of pregnancy using cell-free fetal DNA, cell-free total DNA, and biochemical markers. Fetal Diagn Ther. 2016 Mar 22; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Larrea E, Sole C, Manterola L, Goicoechea I, Armesto M, Arestin M, et al. New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci. 2016;17.pii:E627.
   Web of Science ®Google Scholar
• Pineles BL, Romero R, Montenegro D. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol. 2007;196:261.
   PubMed Web of Science ®Google Scholar
• Ishibashi O, Ohkuchi A, Ali MM, Kurashina R, Luo SS, Ishikawa T, et al. Hydroxysteroid (17-β) dehydrogenase 1 is dysregulated by miR-210 and miR-518c that are aberrantly expressed in preeclamptic placentas: a novel marker for predicting preeclampsia. Hypertension. 2012;59:265–73.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhou Y, Zhang Z. MiR-210: an important player in the pathogenesis of preeclampsia?. J Cell Mol Med. 2012;16:943–4.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fei M, Xue G, Zhou Q, Jia Y, Li L, et al. Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia: new insights into molecular mechanisms for the disease. J Cell Mol Med. 2012;16:249–59.
   PubMed Web of Science ®Google Scholar
• Anton L, Olarerin-George AO, Schwartz N, Srinivas S, Bastek J, Hogenesch JB, et al. miR-210 inhibits trophoblast invasion and is a serum biomarker for preeclampsia. Am J Pathol. 2013;183:1437–45.
   PubMed Web of Science ®Google Scholar
• Li Q, Long A, Jiang L, Cai L, Xie LI, Gu J, et al. Quantification of preeclampsia-related microRNAs in maternal serum. Biomed Rep. 2015;3:792–6.
   PubMed Web of Science ®Google Scholar
• Zhu XM, Han T, Sargent IL, Yin GW, Yao YQ. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. Am J Obstet Gynecol. 2009;200:661.
   PubMed Web of Science ®Google Scholar
• Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D, Chidambaram K, Williams MA. Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2011;204:178.
   PubMed Web of Science ®Google Scholar
• Noack F, Ribbat-Idel J, Thorns C, Chiriac A, Axt-Fliedner R, Diedrich K, et al. miRNA expression profiling in formalin-fixed and paraffin-embedded placental tissue samples from pregnancies with severe preeclampsia. J Perinat Med. 2011;39:267–71.
   PubMed Web of Science ®Google Scholar
• Betoni JS, Derr K, Pahl MC, Rogers L, Muller CL, Packard E, et al. MicroRNA analysis in placentas from patients with preeclampsia: Comparison of new and published results. Hypertens Pregnancy. 2013;32:321–39.
   PubMed Web of Science ®Google Scholar
• Kotlabova K, Doucha J, Hromadnikova I. Placental-specific microRNA in maternal circulation–identification of appropriate pregnancy-associated microRNAs with diagnostic potential. J Reprod Immunol. 2011;89:185–91.
   PubMed Web of Science ®Google Scholar
• Luque A, Farwati A, Crovetto F, Crispi F, Figueras F, Gratacós E, et al. Usefulness of circulating microRNAs for the prediction of early preeclampsia at first-trimester of pregnancy. Sci Rep. 2014;4:4882.
   PubMed Web of Science ®Google Scholar
• Akehurst C, Small HY, Sharafetdinova L, Forrest R, Beattie W, Brown CE, et al. Differential expression of microRNA-206 and its target genes in preeclampsia. J Hypertens. 2015;33:2068–74.
   PubMed Web of Science ®Google Scholar